Faron, etusivu

releases and announcements

Results of EGM

Regulatory

Holding(s) in Company

Shareholder announcement Regulatory

Registration of New Shares

Regulatory

Announcement of Placing

Regulatory

Faron notice of EGM

Regulatory

Faron Announces Top-Line 12-Month Survival Results

Regulatory

First Patient Dosed in Ph I/II BEXMAB Combo Study

Exercise of options

Regulatory

Presentation of Biomarker Analysis at ASCO

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

Regulatory
PreviousNext
Back to top